ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

Heart Failure With Preserved Ejection Fraction (HFpEF)

Amaninderapa Ghotra

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Hypertension 2025: New Guidelines and Resistant Hypertension

University of Louisville

K. Ferdinand

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

An Efficient Approach to Addressing Syncope in the Office

Dr. Vu Kiet Tran

V. Tran

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

Hypertrophic Cardiomyopathy: the Past, the Present, and the Future

Collaborative CME and Research Network

E. Braunwald

Benefits of Slowing the Heart with Ivabradine

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran